Skip to main content

Table 1 Members of the IRDiRC Working Group on Goal 3 (WG3)

From: Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients

Name

Affiliation

Patrizio Armeni

SDA Bocconi School of Management, Milan, Italy

Dimitrios Athanasiou

MDA Hellas, Athens, Greece

Alicia Bauskis

Department of Health, Western Australia, Perth, Australia

John Belmont

Illumina, San Diego, CA, USA

Anna Bucsics

Mechanism of Coordinated Access to orphan medicinal products (MoCA), Vienna, Austria

Peter Fish

Mendelian, London, UK

Josie Godfrey

JG Consulting, London, UK

Daniel Ollendorf

Tufts Medical Center, Boston, MA, USA

Manuel Posada

Institute of Rare Diseases Research, Institute of Health Carlos III, Madrid, Spain

Michael Schlander

University of Heidelberg, Heidelberg, Germany

Vicky Seyfert-Margolis

My Own Med, Inc., Bethesda, MD, USA

David A. Pearce

Sanford Health, Sioux Falls, SD, USA

Galliano Zanello

IRDiRC Scientific Secretariat, Inserm, Paris, France